Wuxi Apptec Co., Ltd. Class A · SSE:603259
Wuxi Apptec Co., Ltd. Class A — Investor Day (2024)
36 slides from Wuxi Apptec Co., Ltd. Class A's investor day presentation, 2024
Slide 1: Research Enabling Platforms Enhance CRDMO Model
2 0 2 4 W u X i A p p Te c I n v e s t o r D a y Research Enabling Platforms Enhance CRDMO Model Steve Yang, Ph.D. Co-CEO 1
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation may contain certain statements that are or may be forward looking, which can be recognized by the use of words such as “expects”, “plans”, “will”, “estimates”, “projects”, “intends”, or words of similar meaning. Such forward-looking statements are not his
Slide 3: WuXi Chemistry, Biology, and Testing Collaborate at Research Stage to Enhance CRDMO Business Model
WuXi Chemistry, Biology, and Testing Collaborate at Research Stage to Enhance CRDMO Business Model Generate the Flow Discovery by enabling discovery and research Preclinical Understand the Trends by following science and customers WuXi Chemistry Achieve Synergy through PCC & WuXi WuXi Biology Testin
Slide 4: Enable Innovation at Research Stage
Enable Innovation at Research Stage WuXi Chemistry Design Analyze Deliver PCC Enable IND Discover Targets Develop and Run Assays Demonstrate Efficacy Prepare for FIH Study WuXi Biology WuXi Testing Capacity Capability Quality Synergy 4 Note: PCC, Preclinical Candidate; IND, Investigational New Drug;
Slide 5: Attract New Customers to WuXi AppTec CRDMO Platform
Attract New Customers to WuXi AppTec CRDMO Platform ~69% Attract New of WuXi AppTec new customers Customers are contributed by Discovery + Preclinical in 2023 of Discovery + Preclinical 2023 new biotech ~28% customers* have fund raising events after 2019 Notes: 1. Including Discovery and Preclinical
Slide 6: Generate the Flow of Compounds and Projects Through Chemistry
Generate the Flow of Compounds and Projects Through Chemistry • During 2023H2 to 2024H1, Research Chemistry Services (RCS) delivered: • Over 450, 000 Compounds Number of compounds delivered 425,445 402,363 314,919 237,084 230,273 2020 2021 2022 2023 2024H1 6
Slide 7: Enhance Customer Engagement through Integrated Services
Enhance Customer Engagement through Integrated Services # of Customers use both Discovery & Preclinical platforms 800+ 900+ 700+ 2021 2022 2023 73.2% Revenue% of customers 72.4% use both Discovery & 71.0% Preclinical platforms 2021 2022 2023 7 Note: Discovery represents WuXi Biology and RCS (Researc
Slide 8: Reach More Long Tail Customers and Attract Them to CRDMO Platform
Reach More Long Tail Customers and Attract Them to CRDMO Platform Industry News Public Information Third-Party Databases 300,000+ Organizations Data Points Business WuXi AppTec Success Data Platforms Indicators Follow the Business • Molecule Analysis • Disease • Customer Systematic Potential Rule-ba
Slide 9: Understand the Trends & Build New Capability Through the Flywheel Model
Understand the Trends & Build New Capability Through the Flywheel Model Value to Customers Follow the science & support early adopters / pioneer customers Explore early mover advantages to Early experiment with new technologies and Early solutions Accumulate expertise & Build new The speed for proje
Slide 10: Infectious Disease Market Expansion
Infectious Disease Market Expansion ~23% 9 drugs on 4 in market phase Ⅲ of active customers in market* collaborate with us since 2021 Notes: 1. According to internal analysis. 2. Including Discovery and Preclinical customers. 3. Discovery represents WuXi Biology and RCS (Research Chemistry Services)
Slide 11: Capability Building Flywheel for Oncology
Capability Building Flywheel for Oncology End-to-end services and •System solutions to enable cancer ~32% •Standard •Process drug discovery • 1,200+ cell lines and 4,000+ disease models •Capability of active customers in market* Project •Technology • 14,000+ cancer pharmacology and collaborate with
Slide 12: In vivo Pharmacology Integration Across Therapeutic Areas
In vivo Pharmacology Integration Across Therapeutic Areas Oncology ~32% •System •Standard •Process Immunology & Inflammation ~32% •Technology Project •Capability Delivery •Know-how Metabolic Disease ~30% •Efficiency •Speed •Quality Neuroscience ~30% Notes: 1. Numbers shown on this page represent the
Slide 13: Small Molecule Market Expansion
Small Molecule Market Expansion Research Chemistry Services (RCS) synthesized over 450,000 compounds from 2023H2 to 2024H1. ~42% The application of Flow Chemistry and Photochemistry Technologies benefits over 90% of of active customers in market* our long-term partners. collaborate with us since 202
Slide 14: Early Capability Building in Emerging Technologies
Early Capability Building in Emerging Technologies OBOC Bispecific antibody ADC Stem cell Oncolytic viruses Target Protein Degradation Single-cell and spatial multi-omics 2015 2019 2021 2023 2014 2016 2020 2022 Cancer vaccine Fusion protein CAR-T / Cell Therapy Tumor Infiltrating Peptide RNA Oligonu
Slide 15: New Modality Market Expansion
New Modality Market Expansion ~26% of active customers in market* collaborate with us since 2021 • Targeted Protein Degradation • Oligonucleotide/RNA/Antisense • ADC/PDC/AOC • Cancer Vaccine / Oncolytic virus / Stem Cell / Exosomes • Vector Platform/ Novel Drug Delivery Vehicle Note.: 1. According t
Slide 16: Multi-Modality Expansion Supports Drug Discovery - Biology
Multi-Modality Expansion Supports Drug Discovery - Biology 27.5% 2019 2020 2021 2022 2023 2019 2020 2021 2022 2023 Revenue from New Modalities New Modalities & Biologics & Biologics Contribution to Total Revenue 16 Note: WuXi Biology data only.
Slide 17: Nucleic Acid Therapeutics Market Expansion
Nucleic Acid Therapeutics Market Expansion Biology Revenue ~25% +73% YOY (2023 vs 2022) Capability and capacity of active customers in market* Quality and turnround time collaborate with us since 2021 Experience Solution provider Nucleic Acid Therapeutics Notes: 1. According to internal analysis. 2.
Slide 18: Capability Building on Bi-Functional Degraders at WuXi Biology
Capability Building on Bi-Functional Degraders at WuXi Biology Rapid Establishment and Expansion of Capability and Know-how DAC Early Capability set up during the first wave of targeted protein degrader RIBOTAC candidates PHICS 2024 Fast Comprehensive platforms established DUBTAC in short period 202
Slide 19: Targeted Protein Degrader (TPD) Integrated Discovery Platform
Targeted Protein Degrader (TPD) Integrated Discovery Platform Chemistry Biology • >1000 discovery chemists, with • >8 years of providing biology strong experiences in the linkers, solutions to TPD E3 ligase ligands and target protein ligands synthesis since • Built >20 assay technologies to 2016 TPD
Slide 20: Targeted Protein Degrader Market Expansion
Targeted Protein Degrader Market Expansion ~66% of active customers in market* collaborate with us since 2021 Targeted Protein Degrader Notes: 1. According to internal analysis. 2. Including Discovery and Preclinical customers. 3. Discovery represents WuXi Biology and RCS (Research Chemistry Service
Slide 21: Innovation Forefront: Enable New Biotech Companies to Discover & Develop Lifesaving Medicines
Innovation Forefront: Enable New Biotech Companies to Discover & Develop Lifesaving Medicines from Breakthrough Sciences Case Study: Partnership with Yale University Professor Craig Crews from Arvinas and Halda Therapeutics, WuXi AppTec was the Very First Company to Support PROTAC® and RIPTACTM Drug
Slide 22: Harness the Power and Scale of Scientific Instruments
Harness the Power and Scale of Scientific Instruments & Deliver Success, Speed, and Efficiency to Customers Advantages in Advantages in Use Cases Hardware Capability HPLC 700+ Method Development Analysis Purification Problem Solving Mass Spec 700+ Traditional Automation Small NewNew Modalities Other
Slide 23: Drive Efficiency Through Automation: Bioanalytical Service
Drive Efficiency Through Automation: Bioanalytical Service Efficiency • Automated sample processing platform • Digital information & lab automation system Cutting-edge Technology • Ultra-high sensitive peptide bioanalytical method (Picogram level) • Comprehensive Oligo testing capabilities (Femtogra
Slide 24: Drive Efficiency Through Automation: DMPK
Drive Efficiency Through Automation: DMPK Efficiency • TAT full process tracking and enhancement • PK project intelligent scheduling Cutting-edge Technology • “Peptide / PDC MetID” solution self-developed • European standard testing facility established • Radiosynthesis platform 24 Note: TAT: Turn-A
Slide 25: Drive Efficiency Through Automation: Toxicology
Drive Efficiency Through Automation: Toxicology Efficiency Real time • Machine learning and automation technology Vivarium Planning Information Sharing widely applied in toxicology business Technicians work Automated Checking Digital Project Management Scheduling • Advanced algorithm for assignment
Slide 26: Integrated Preclinical Enabling Platform Across All Modalities
Integrated Preclinical Enabling Platform Across All Modalities WuXi Chemistry WuXi Global Market WuXi Biology Testing • 6 Sites: • Automatic Full Process: • One-stop solution: • Global filling: - GLP: SZ˙CD˙QD - TAT tracking - From “D” to “T” - NMPA - Non-GLP: SH˙NJ˙US - Study management - From “R”
Slide 27: Drive Preclinical Conversion Through CRDMO Business Model
Drive Preclinical Conversion Through CRDMO Business Model WuXi Testing 960+ IND# projects Total WuXi Chemistry 650+ Global Market WuXi Biology Ongoing IND 290+ Joint IND projects# projects# 670+ IND projects# WuXi Testing 310+ IND Projects# Enabling study completed. Progress to filing. 27 Note: IND
Slide 28: Seamless Collaboration: One-Stop Integrated IND Solution
Seamless Collaboration: One-Stop Integrated IND Solution Revenue $ IND Project # WuXi Chemistry and WuXi Biology Joint WuXi Chemistry and WuXi Biology Joint H2 30%+ 960+# H1 H1 WuXi Chemistry IND # WuXi Testing WuXi Biology 2021 2022 2023 2024 28 Note: Revenue from IND projects joint by WuXi Chemist
Slide 29: Strong Momentum For Preclinical IND Project Flow
Strong Momentum For Preclinical IND Project Flow +200% IND project # 2024 H1 vs 2023 H1 Peptide project# siRNA project# ADC project# +700% +450% +150% 29
Slide 30: Well Established Peptide Preclinical Testing Capabilities Since 2015
Well Established Peptide Preclinical Testing Capabilities Since 2015 90+ Clients served 5 Market peptide drugs enabled Peptide bioanalysis 2024 platform established 2023 2017 • Microflow liquid chromatography 7500+ mass spectrometry 2015 • Achieve picogram level of bioanalytical methods, ahead of th
Slide 31: Trusted Preclinical Testing Platform Enables Global Licensing
Trusted Preclinical Testing Platform Enables Global Licensing 67% Enabled out licensing of ADC molecules in 2024 H1 80%+ 52% Enabled out licensing of small molecules in 2024 H1 31
Slide 32: Meeting Global Quality Standard
Maintain the Highest Global Regulatory Standards 120,000 m2 AAALAC BSL-2 Multiple Sites GLP Facility One Standard GLP NMPA Meeting Global Quality Standard 32
Slide 33: Case Study: WuXi AppTec "Race Car" Enables Innovation
Case Study: WuXi AppTec “Race Car” Enables Innovation RCS (R) LTD (T) STA (D) • High Chemical Complexity • Seamless Transition Testing Sam Clark, CEO, Terran Bioscience • Key Client Urgent Project • Patent Submission Date • Client Collaboration with • Supply of Intermediate Raw We would not have bee
Slide 34: Achieve Customer Satisfaction and Maintain High Retention Rates
Achieve Customer Satisfaction and Maintain High Retention Rates 98% 98% 97% 2024H1 2023 2022 TOP 300 Notes: 1. TOP 300 WuXi Discovery + Preclinical customers. 34 2. Retention: the ratio that TOP 300 customers in revenue of previous year which still work with us this year.
Slide 35: Continue Increase of the Number of Active Customers Across Globe
Continue Increase of the Number of Active Customers Across Globe +5.1% +7.5% +3.3% North America EU Asia & Others 23H1 vs 24H1 23H1 vs 24H1 23H1 vs 24H1 23H1 24H1 23H1 24H1 23H1 24H1 Notes: 1. Numbers shown on this page represent the YoY% of active customers. 2. Including Discovery and Preclinical c
Slide 36: Integrated Research Platform Enabling CRDMO Business Model
Integrated Research Platform Enabling CRDMO Business Model One-Stop Solution at WuXi AppTec WuXi Chemistry WuXi Biology WuXi Testing WuXi Biology Med Chem, Hit Finding ADME/Tox Synthesis and Hit to Lead DMPK Manufacturing Lead Optimization IND-Enabling and Packaging ——————————————— WuXi AppTec——————